Project Affinity: Excess Cancer Blood Testing

Study investigating cancer blood samples on an iterative measurement systme

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Christie NHS Foundation Trust

Manchester, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Undergoing SACT
Routine blood tests

Exclusion criteria

Not had first cycle of SACT

Treatment and study plan

No drug

Other

No drug used

Primary outcomes

Viability of measurement technique

Time frame: 12 months

Viability of measurement technique

Sponsors and collaborators

Lead sponsor

Entia Ltd

Industry

Registry information

Official study title

Project Affinity: Excess Cancer Blood Testing Technique

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Jan 26, 2021
Registry last updated: Sep 29, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed